Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca’s (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY), would be added for reimbursement by state-run medical insurance in China, the country’s health officials announced Thursday.
Enhertu’s addition to China’s National Reimbursement Drug List